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Differential splicing removing exon 3 (with dominant 




743 amino acids; 80 kDa; N-term acidic transcriptional 
activation domain (domain 260-271, exon 3), helix-
loop-helix (344-400), leucine zipper (409-430), and a 
proline/arginine rich sequence (575-743) C-term. 
Expression 






Transcription factor; member of the basic helix-loop-
helix family (b-HLH) of transcription factors primarily 
found to bind to the immunoglobulin enchancer muE3 
motif, Ig K enhancers and Ig H variable regions 
promotors; the helix-loop-helix - leucine zipper region 
is implicated in DNA binding and dimerization (homo 
and heterodimerizations); mice which lack TFE3 in 
their B and T lymphocytes reconstitute the B- and T-
cell compartments, but IgM levels are reduced. 
Homology 
To other members of the myc family of helix-loop-
helix transcription factors. 
Implicated in 
t(X;1)(p11.2;q21.2) in renal cell 
carcinoma --> PRCC/TFE3 
Prognosis 
Overall 5-year survival rate around 85%. 
Hybrid/Mutated gene 
5' PRCC - 3' TFE3; variable breakpoint in PRCC; 
breakpoint in the 1st intron of TFE3. 
Abnormal protein 
N-term PRCC with the proline rich sequence fused to 
most of TFE3, including the acidic transcriptional 
activation domain, the helix-loop-helix, and the leucine 
zipper; the reciprocal TFE3-PRCC is expressed; it is to 
be noted that the normal TFE3 transcript is lost in 
female patients. 
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t(X;1)(p11.2;p34) in renal cell carcinoma 
--> PSF/TFE3 
Disease 
t(X;1)(p11.2;p34) has only been found in a handfull 
cases of papillary renal cell carcinoma. 
Hybrid/Mutated gene 
5' PSF - 3' TFE3. 
Abnormal protein 
N-term PSF and most of it fused to the DNA binding 
domains of TFE3 (excluding the acidic transcriptional 
activation domain, including the C-term helix-loop-
helix, and the leucine zipper); no TFE3-PSF reciprocal 
transcript, as the der(X) t(X;1) is missing; the normal 
TFE3 transcript is found. 
 
 
inv(X)(p11.2q12) in renal cell carcinoma 
--> NONO/TFE3 
Disease 
Only one case of papillary renal cell carcinoma. 
Hybrid/Mutated gene 
5' NONO - 3' TFE3. 
Abnormal protein 
N-term NONO and most of it except the C-term proline 
rich sequence fused to the DNA binding domains of 
TFE3 (excluding the acidic transcriptional activation 
domain, including the C-term helix-loop-helix, and the 
leucine zipper); the reciprocal transcript is found. 
 
Other Xp11 involvements in renal cell 
carcinoma (t(X;17)(p11;q25), 
t(X;10)(p11;q23), etc ...) are likely to 
implicate TFE3. 
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